Characterisation of Occupational Allergy to Drosophila (DROSOALLERG)

April 11, 2016 updated by: University Hospital, Montpellier
Allergy is a very common problem and can be a handicap in everyday life, specially when symptoms occur at work place. Some persons working with drosophila developed respiratory symptoms. Investigators tried to analyze if these manifestations could be due to a specific allergy to drosophila.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

To do so, investigators invited laboratory workers who presented any symptoms in presence of drosophila to undergo skin prick tests in order to determine if a specific sensibilization to drosophila exists. Then, a blood sample is taken from these persons to research specific IgE directed against drosophila. By this way, investigators hope determine if a specific allergy to drosophila exists, its characteristics as prevalence, symptoms, populations concerned...in order to better protect laboratory workers and prevent allergy incidence.

Study Type

Interventional

Enrollment (Actual)

12

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Montpellier, France, 34295
        • Hôpital Arnaud de Villeneuve

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 68 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • major males or females (aged <68) who work in laboratory with drosophila in Montpellier (France)
  • clinical symptoms in presence of drosophila
  • The subject must be affiliated to a social security scheme
  • Provision of informed consent prior to any study specific procedures

Exclusion Criteria:

  • The patient has indicated against (or incompatible drug combination) concerning the implementation of a prick test
  • antihistamine cure in progress
  • Inability to understand the nature and goals of the study and / or communication difficulties with the investigator
  • No affiliation to a French social security recipient or not such a scheme
  • Major protected by law (guardianship, curator or under judicial protection)
  • deprivation of liberty by judicial or administrative decision
  • Increased likelihood of non compliance to the protocol or abandonment under study
  • pregnancy or breastfeeding

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: laboratory workers with symptoms in presence of drosophila
Other: blood test (four dry tubes 7ml) and prick tests

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants with positive prick test to drosophila
Time Frame: The day of inclusion
Prick tests : measuring the size of the skin reaction (wheal) after prick tests with drosophila. A wheal measuring more than 4 millimeters in diameter sign a sensitization to drosophila. Then, a blood sample is collected in order to measure specific drosophila IgE rate
The day of inclusion

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Survey to analyse risk factors for allergy to drosophila
Time Frame: The day of inclusion
analysis of professional (attended institute, time from start working with drosophila, type of animal manipulation (species, living, dead, DNA, protein) use of protection,) or personal factors (age, gender, others allergies, treatment used) which could lead to allergic reaction to drosophila
The day of inclusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Montpellier

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2014

Primary Completion (Actual)

February 1, 2015

Study Completion (Actual)

February 1, 2015

Study Registration Dates

First Submitted

August 20, 2015

First Submitted That Met QC Criteria

August 26, 2015

First Posted (Estimate)

August 31, 2015

Study Record Updates

Last Update Posted (Estimate)

April 12, 2016

Last Update Submitted That Met QC Criteria

April 11, 2016

Last Verified

April 1, 2016

More Information

Terms related to this study

Other Study ID Numbers

  • UF 9410

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on blood test (four dry tubes 7ml) and prick tests

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe